LPCN

Lipocine is a $17M-market-cap clinical-stage biopharma with no product revenue — its top line is entirely lumpy TLANDO license/milestone income, which swung from $16.1M (FY21) to $500K, to negative $2.85M, to $11.2M, and back to just $1.98M in FY2025 (-82.3% YoY). That volatility is not a business you can underwrite; management itself states in the MD&A that it 'has not generated any revenues from product sales' and does not expect product revenue 'unless and until approval' of its candidates. On $1.98M of revenue the company posted a -$9.63M net loss, a -524.7% operating margin, and burned -$9.76M in operating cash flow while spending $8.58M on R&D. Retained earnings sit at -$209M — two decades of accumulated deficit.

The binding constraint is liquidity. Cash and equivalents are $5.21M against ~$9.8M annual cash burn — well under a year of runway at the current pace. Financing 'primarily through sales of equity securities' is the stated model, and shares already grew 36.4% YoY to 7.30M; a 7.3M-share float against this burn means further raises are near-certain and highly dilutive at a depressed $2.39 price. The balance sheet looks clean on a liabilities/equity basis (0.17x, $2.53M liabilities), but equity fell 31.1% YoY and is being consumed by losses, not leverage — the risk is running out of money, not defaulting on debt.